Revenue
2016
2017
2018
2019
2023
2024
2025
Dianthus Therapeutics, Inc. /DE/ (DNTH)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2016
2017
2018
2019
2020
2021
2022
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $6.2M | $2.8M | — | — | — | $0 | $0 | $0 | $0 |
| Research & development | $145.6M | $83.1M | $32.8M | $29.4M | $46.8M | $50.6M | $59.2M | $41.3M | $27.9M | $5.8M |
| Operating expenses | $180.0M | $108.1M | $51.0M | $36.1M | $74.7M | $78.7M | $83.0M | $60.0M | $35.7M | $9.3M |
| Operating income | −$177.9M | −$101.9M | −$48.2M | −$29.7M | −$74.7M | −$78.7M | −$83.0M | −$60.0M | −$35.7M | −$9.3M |
| EBITDAderived | — | — | — | −$27.8M | −$72.7M | −$76.7M | −$81.1M | −$59.1M | −$35.4M | −$9.3M |
| Net income | −$162.3M | −$85.0M | −$43.6M | −$28.5M | −$71.1M | −$74.9M | −$76.8M | −$57.5M | −$35.5M | −$9.4M |
| Basic EPSper diluted share | -$4.20 | -$2.55 | -$8.45 | -$32.57 | -$1.29 | -$1.71 | -$2.07 | -$3.13 | -$19.12 | -$65.15 |
| Diluted EPSper diluted share | -$4.20 | -$2.55 | -$8.45 | -$32.57 | -$1.29 | -$1.71 | -$2.07 | -$3.13 | -$19.12 | -$65.15 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 17, 2026Form 4 · 10b5-1 | Veness Adam MSVP, General Counsel and Sec. | SellCommon Stock | 13.2K | $81.38 | $1.08M | 0 |
| Jun 17, 2026Form 4 · 10b5-1 | Veness Adam MSVP, General Counsel and Sec. | SellCommon Stock | 16.8K | $80.34 | $1.35M | 13.2K |
| Jun 1, 2026Form 4 · 10b5-1 | Randhawa SimratEVP, Head of R&D | SellCommon Stock | 4.2K | $91.37 | $380.0K | 4.0K |
| Jun 1, 2026Form 4 · 10b5-1 | Randhawa SimratEVP, Head of R&D | SellCommon Stock | 16.9K | $90.72 | $1.54M | 8.2K |
| Jun 1, 2026Form 4 · 10b5-1 | Randhawa SimratEVP, Head of R&D | SellCommon Stock | 5.4K | $89.72 | $487.0K | 25.1K |